Table 2.

Independent contribution of rs12979860 and TT/-G to HCV clearance

Response to treatment Polymorphisms included in the same model 
 OR (95% CI) 
All viral genotypes; n = 540   
Polymorphisms by pairs   
TT/-G 0.12 (0.03–0.40) 5.94−4 
rs12979860 3.41 (1.01–11.4)a 4.77−2 
Viral genotypes 1 and 4, n = 288   
Polymorphisms by pairs   
TT/-G 0.16 (0.05–0.55) 3.60−3 
rs12979860 1.61 (0.48–5.40)a 4.44−1 
Spontaneous clearanceb   
Polymorphisms by pairs   
TT/-G 0.42 (0.14–1.30) 1.31−1 
rs12979860 0.66 (0.22–1.99) 4.59−1 
Response to treatment Polymorphisms included in the same model 
 OR (95% CI) 
All viral genotypes; n = 540   
Polymorphisms by pairs   
TT/-G 0.12 (0.03–0.40) 5.94−4 
rs12979860 3.41 (1.01–11.4)a 4.77−2 
Viral genotypes 1 and 4, n = 288   
Polymorphisms by pairs   
TT/-G 0.16 (0.05–0.55) 3.60−3 
rs12979860 1.61 (0.48–5.40)a 4.44−1 
Spontaneous clearanceb   
Polymorphisms by pairs   
TT/-G 0.42 (0.14–1.30) 1.31−1 
rs12979860 0.66 (0.22–1.99) 4.59−1 

Both TT/-G and rs12978960 were introduced in the same logistic regression model. OR, odds ratio; CI, confidence interval. OR represent the additive effect of the mutant allele (-G for TT/-G and T for rs12979860).

a

When TT/-G was entered into the model, the direction of the association of the T allele of rs12979860 was reversed (OR > 1).

b

93 individuals with spontaneous HCV clearance were compared to 540 patients with chronic infection

or Create an Account

Close Modal
Close Modal